Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status (Q43244728)

17 November 2017

Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status (English)

1 reference

17 November 2017

Amar Nagila

1

1 reference

17 November 2017

Thinnakorn Permpongpaiboon

2

1 reference

17 November 2017

Soontharee Tantrarongroj

3

1 reference

17 November 2017

Pornwalee Porapakkham

4

1 reference

17 November 2017

Kultira Chinwattana

5

1 reference

17 November 2017

Sara Deakin

6

1 reference

17 November 2017

Sureerut Porntadavity

7

1 reference

17 November 2017

1 September 2009

1 reference

17 November 2017

Pharmacological Reports

1 reference

17 November 2017

61

1 reference

17 November 2017

5

1 reference

17 November 2017

892-898

1 reference

Does paraoxonase play a role in susceptibility to cardiovascular disease?

17 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Polymorphisms in the human paraoxonase (PON1) promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Microsomal lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase, a cardioprotective enzyme: continuing issues

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The molecular basis of the human serum paraoxonase activity polymorphism.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Increased oxidative stress in children exposed to passive smoking

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Beyond lipid lowering: the role of statins in vascular protection

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The paraoxonase gene family and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The past, the present and the future of experimental research on myocardial ischemia and protection

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Effects of atorvastatin on inflammation and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Novel molecules targeting dyslipidemia and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

Statin therapy: beyond cholesterol lowering and antiinflammatory effects

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970146-X

7 January 2021

10.1016/S1734-1140(09)70146-X

Identifiers

DOI

1 reference

17 November 2017

1 reference